News & Updates

Show Multimedia Only
Dual glucagon/GLP-1 RA survodutide shows broad benefits in phase III obesity & MASLD trials
Dual glucagon/GLP-1 RA survodutide shows broad benefits in phase III obesity & MASLD trials
19 hours ago

Survodutide, a glucagon receptor–glucagon-like peptide-1 (GLP-1) receptor dual agonist, significantly reduces body weight and liver/visceral fat in individuals with obesity as well as those with obesity and at-risk metabolic dysfunction–associated steatotic liver disease (MASLD) in the phase III SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials. The data, presented at ADA 2026, also demonstrate improvements in cardiometabolic parameters indicating broad benefits associated with survodutide treatment. 

Dual glucagon/GLP-1 RA survodutide shows broad benefits in phase III obesity & MASLD trials
19 hours ago